Collaboration, Licensing and Other Arrangements - Schedule of Revised Anticipated Cash Flows from Transactions Allocated Performance Obligations (Detail) - Collaboration and License Agreement - United Therapeutics Corporation $ in Millions	1 Months Ended
	Dec. 31, 2022 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total anticipated cash flows	$ 722.3	[1]
R&D Services and License | Over Time
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Progress Measure	Ratably
Recognition Period	Aug 2021 - Oct 2021
Next-Gen R&D Services | Over Time
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Anticipated Revenue Allocation	$ 10.0
Progress Measure	Input
Recognition Period	% of completion of costs
Manufacturing Services and Product Sales | Point In Time
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Anticipated Revenue Allocation	$ 712.3	[2]
Recognition Period	Transfer of control	[2]

[1] The total anticipated cash flow includes a transaction price of $120.0 million for the contractual obligations under the CSA for the Manufacturing Services and the Next-Gen R&D Services performance obligations and $602.3 million for future supply of Tyvaso DPI over the remaining term of the CSA.

[2] The Manufacturing Services performance obligation will be recognized as control of manufactured products is transferred to UT. The modification did not result in a cumulative catch-up adjustment as a result of the revenue being deferred for the performance obligations that were affected by the modification. The allocation of the transaction price for the Manufacturing Services includes a material right related to the Company’s estimated production of product in the amount of $220.8 million. The Company will sell product to UT under individual purchase orders, which represent distinct performance obligations. The ultimate cash flows may vary as manufacturing purchase orders are received.